Neurocrine Biosciences, Inc. (NBIX)
132.03
+1.07
(+0.82%)
USD |
NASDAQ |
Feb 25, 15:29
Neurocrine Biosciences Research and Development Expense (Quarterly) : 258.20M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Glaukos Corp. | 43.65M |
| Edgewise Therapeutics, Inc. | 36.96M |
| Nuvalent, Inc. | 83.84M |
| Marker Therapeutics, Inc. | 2.346M |
| CapsoVision, Inc. | 6.09M |